NDAORALTABLETPriority Review
Approved
Dec 2023
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
IWILFIN (eflornithine hydrochloride) by AbbVie is (odc), the first and rate-limiting enzyme in the biosynthesis of polyamines and a transcriptional target of mycn . First approved in 2023.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IWILFIN (eflornithine hydrochloride) is an oral small-molecule inhibitor of ornithine decarboxylase (ODC) approved for MYCN-amplified neuroblastoma. It works by blocking polyamine biosynthesis, restoring the LIN28/Let-7 pathway and suppressing oncogenic drivers MYCN and LIN28B. The drug induces senescence and prevents tumor formation in preclinical models.
Growth9.6 years to LOE
Early-stage growth product with no direct competition, creating opportunity for commercial team expansion and market development.
Mechanism of Action
(ODC), the first and rate-limiting enzyme in the biosynthesis of polyamines and a transcriptional target of MYCN . Polyamines are involved in differentiation and proliferation of mammalian cells and are important for neoplastic transformation. Inhibition of polyamine synthesis by eflornithine…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on IWILFIN offers deep specialization in rare pediatric oncology with no competitive pressure, creating focused territory management and strong relationships with specialist centers. The early growth phase and 9+ years of patent protection provide job security and career stability through the mid-2030s.
Worked on IWILFIN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.